Autres langues Celularity Inc.

Actions

CELU

US1511902041

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
3,38 ^USD	+5,30 %		+2,11 %	+36,62 %

26/03	Celularity reçoit l'approbation du code Q du Healthcare Common Procedure Coding System (HCPCS) des U.S. Centers for Medicare & Medicaid Services pour Biovance 3L	CI
20/03	Celularity demande à la FDA le statut de médicament orphelin pour le PDA-002 dans la dystrophie musculaire facio-scapulo-humérale	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Celularity Inc. to Host Investor and Analyst Research and Development Day	23/04
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	22/04
Celularity Inc. to Host Investor and Analyst Research & Development Day	22/04
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	19/04
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024	18/04
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024, Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	16/04
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	15/04
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells	08/04
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L	26/03
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	26/03
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	20/03
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy	20/03
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit	14/03
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	13/03
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress	12/03
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells	07/03
Celularity to Execute Reverse Stock Split Next Week	23/02
Celularity Announces 1-for-10 Reverse Stock Split	23/02
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease	14/02
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline	01/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celularity Inc.

Actions

CELU

US1511902041

Autres langues

Filtres